Could be a long slow smoke for them too...as the good ER today could very well lead to a long protracted rise. Finally, some good news for longs.
Two issues here. 1. You can't R/S your way to a national exchange. 2. $2 share isn't going to meet requirements as there is no way AMBS will hold that level following an R/S. Just ask ZLCS how their R/S worked out to keep their place ON a national exchange. R/S would need to be more like 50 to 1 and even that might not do it. Either way GC is going to dilute big time after an R/S or after the cap is raised. Maybe he'll do both. Raise the A/S to 2 B and then a 50 to 1 RS. Nothing this guy does surprises me anymore as he's just using shareholders to survive long enough to keep seats warm and the long shot that MANF will payoff alive...problem is with Lympro dead the need to finance MANF development still looms. GC needs lots of cash from shareholders to do it. That's where YOU come in. Max pain cometh.
Sentiment: Strong Sell
The difference is Lympro is dead and GC has proven himself to be a completely untrustworthy as a manipulative CEO who doesn't deliver on his promises. The R/S will yield an equivalent sub nickle pps soon enough. But hey, epic news is just a quarter away!
You are delusional. It will be a serious hair cut and then a slow spiral downward. There is no upside to buying before or after the R/S...only long after the pps has stabilized. Now we know why GC hasn't been buying the stock on the open market. 1. He can always write himself new options before the next shareholder meeting. 2. He knew he was going to have to either massively dilute once the 1B cap was raised or an R/S and then fresh round of dilution. Neither of these options will get AMBS to a national exchange....only substantive news about MANF will do that as Lympro is dead and GC has demonstrated he can't be trusted. 20 for 1 R/S means a ~$2.2 pps will quickly fall to sub buck territory in a few months.
You would take a 50% haircut after an R/S...either all at once or a slow bleed.
Gerald's been loud and clear about a great many things that he's then reversed himself on later.
Plus here are some great questions by fibonacci....
Between July 15-31, it is impossible to buy that the company did not know already that the LymPro bridging study will not be fully enrolled, let alone analyzed, submitted, peer-reviewed (which can take 1-6 months). Not even finishing enrolling before C4CT shows that the management (a) lied in the blog, (b) missed the target twice, at AAIC and then at C4CT and/or (c) the management is spinning a failure. Were the investors deliberately misinformed? If not, please explain the following:
a. Is bridging enrollment complete.
b. Is bridging analysis complete.
c. Has bridging data been submitted for publication.
d. Has bridging data been peer-reviewed by referees already.
The chances for an R/S are going to go up in 2H 2014 as GC sees serious pressure from investors to uplist. The problem for Gerald is that the organic share price won't support a move to NASDAQ, assuming his BOD passes SEC muster with NASD, and so an R/S on .05-.15 pps is going to be necessary. GC will also need to dilute in the future once the LPC money runs out...or they run away...so that is a consideration as well.
I don't want anyone to buy this scam, that's why I'm here. My posts over the last few days are the first in months...so I would suggest that you check your medicine cabinet first.
It's unrealistic but you could see a 50/1 R/S to make it happen. The pps will be halved upon the move but it would give Gerald an opportunity to "sell" the uplist before he cranks up the dilution machine again. Pretty sweet game if you think about it. GC: Oh sorry longs, had to do the 50/1 R/S to get off the highly manipulated OTC exchange, RR and Smitty help GC sell this of course, and then GC goes dark for four months while tweeting/blogging a few more carrots and then once it's clear no uplist is going to happen, BAM! more dilution. Think about how sweet this is for Gerlad. With ~800M OS you get the float down to 16M...then you can dump another 10 million shares at a buck or so while maintaining an AS cap at about 200M....then you just run the OS back up as salaries and lavish office digs dictate for those MUST. BE. PAID.
You need a 50 for 1 R/S to make an uplist happen. That will eventually be on the agenda as Lympro is dead and there's nothing else that can get the pps above $2...and realistically you'll need $5 to hedge against the 50% drop that will occur on R/S.
This is so true about the current state of this issue:
"I do not know about numbers of shares. I am a little busy right now, you may be right, I would have to look into it.
They will have enough money so that is fine. This is extremely long term, and so, more shares, beats me. They have printed a few hundred million in the last year or so, so nothing would surprise me. Imagine if you had to print out each share, they would cost more to print then they are worth, lol.
I would not be surprised if they got some folks with money to use Lympro in their studies, but it will not amount to more than enough prs to increase the pps.
As I noted, Opko has a test with similar numbers and no one uses it. Its been out for some time, you can read about it in the Lympro white paper and on Opko web site. Just like the Opko test, there is no place with Lympro with those numbers. Note the pr value, noted above. I would bet money that will happen.
ALL along, Lympro AD v Non AD healthy was in the EIGHTIES, you can look that up at Steiler, so for it to be in the 70s and 80s in TWO consecutive studies is no surprise at all. As I said in one of my first posts on Lympro, the numbers on these things always go lower the more they are studied.
Having listened to Dr. Kirby yesterday, I can tell you that he cringed when he read the PR regarding Lympro that went out today. He is a fine fellow, or so it seemed when I listened to his presentation, interesting.
PRs are the lifeblood of Biotech. Buy at the 200 day MA, more or less, wait for the PRs, and then sell, rinse and repeat. IF you happen to have picked the one in a 100 or so biotech that actually makes it, then you are golden.
So far, GC has stretched this into six years of executive pay and so that is a nice salary. It will go on for some time, although with the increased payroll, they will be drawing more soon from their LPC ( Spelling? ) friends."
It was supposed to be first half...despite repeated promises by GC that THAT WOULD happen. Yet here we are. There will be no uplist until MANF is proven, as LYMPRO is dead now, and that is years away.
If whining is so boring to you why you spend 400+ words lecturing us on it...oh yeah, cause you don't find it boring you just find it annoying - even more annoying is the serial deception by AMBS mgmt but then again, you've never been able to be really bothered by/with that. Why don't you just hold your shares and go away...see I can just toss out random bluster just as good as anyone else.
Bif_j, I guess one is only straight up to you when they excited about the stock and not when the CEO lies and blatantly misleads investors...though I think that says more about you than me. I've had a love/hate relationship with this issue..no question...but until the first of this year I gave GC the doubt. No more. This is the third time he has pulled this nonsense and regardless of where the pumping newsletters take the sp, the fundamental underlying issue is GCs deliberate and serial deceptions in communicating with sincere longs. He can't be trusted no matter how much pumpers try and spin what he says because every time he pumps into a conference the predictable results always flesh out....he's just bidding for time and time and patience are going to run out with serious investors soon enough.
The reality is, he can't. He's just trying to spin old news as fresh and "epic" that's the real issue here and unwitting gullible investors new to pennies keep lapping up what pumpers like RR and smitty keep feeding them. It's rise and repeat here until the money runs dry. GCs game is simple and the only card he can play....it's play musical chairs with the facts long enough to convince NASDAQ to uplist and grab enough lifelines to keep MANF in play...but Lympro is completely dead now.